For the quarter ending 2025-09-30, GRTX made $48K in revenue. -$1,388K in net income. Net profit margin of -2891.67%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 130 | 84 | ||
| General and administrative | 1,306 | 1,051 | ||
| Write-off of acquired intangible asset | 0 | - | ||
| Write-off of goodwill | 0 | - | ||
| Gain on litigation settlement | 0 | - | ||
| Loss from operations | -1,436 | -1,135 | ||
| Interest income | 48 | 60 | ||
| Change in fair value of warrant liability | 0 | 0 | ||
| Foreign currency loss | 0 | 0 | ||
| Loss before income tax benefit | -1,388 | - | ||
| Income tax benefit | 0 | - | ||
| Net loss | -1,388 | -1,075 | ||
| Net loss per share of common stock, basic | -0.01 | 0 | ||
| Net loss per share of common stock, diluted | -0.01 | 0 | ||
| Weighted average number of shares outstanding, diluted | 98,503,430 | 98,503,430 | ||
| Weighted-average shares of common stock outstanding, basic | 98,503,430 | 98,503,430 | ||
Galera Therapeutics, Inc. (GRTX)
Galera Therapeutics, Inc. (GRTX)